

Smilow Update: May 19, 2022

**Dear Colleagues,**

**2022 Wellness Survey**

The Yale New Haven Health annual wellness survey is live. Please take a few minutes to complete the survey and share your perspective with leadership. The survey will be live until the beginning of June and non-responders will receive weekly reminders. Each survey invite is personal--you can find yours by searching your inbox for **#2022YNHHSMedicalProfessionalWellbeingSurvey**. Thank you in advance for your time.

**Administrative Approval for Anti-Cancer or Cancer Supportive Care Medications**

Effective immediately at all Smilow Cancer Hospital ambulatory patient care areas, including York Street Campus, the Smilow Cancer Care Centers, and the Health System Delivery Networks, prior authorization and financial clearance must be obtained before starting anti-cancer or supportive care treatment. To allow for thorough financial clearance review, orders should be placed in EPIC a minimum of 72 business hours prior to the patient's scheduled visit.

Occasionally, authorization is delayed, denied, or cannot be obtained prior to treatment due to urgent clinical need. A **standard operating procedure** has been developed to outline the prior authorization workflow and the responsibility and expectations from clinicians and care teams. This SOP also includes the process for escalation to Lori Pickens, MHA, Senior Vice President and Executive Director of Smilow Cancer Hospital, to request administrative approval to administer anti-cancer or cancer supportive care medications without prior authorization. Please review and contact **Sam Abdelghany, PharmD, MHA, BCOP**, if you have any questions.

**Revised and Renamed Chemotherapy/Biotherapy Consent Form**

The Chemotherapy/Biotherapy Consent Form has been revised and renamed as the Anti-Cancer Therapy Consent to apply to any class of drug and ever-growing number of therapies. In addition, side effects related to circulation, mood, sexuality, and autoimmune reactions were added to the consent. The revised form is available in English and Spanish in their current locations: in Smilow Tools (under Consents Chemo/Biotherapy), in Via Oncology under each clinical protocol selection, in the e-consent option, and in the YNH Print Center.

Translated versions of the new consent form in additional 15 languages can also be found in the Print Center. Staff responsible for scanning the signed paper consent forms should continue to file the Anti-Cancer Therapy Consent under the Consent for Chemotherapy/Biotherapy Tab.

### **Pharmacogenomic Panel Testing for Newly Diagnosed Patients with GI Malignancies with Potential for 5-FU-Based Adjuvant Therapy**

Patients with newly diagnosed GI malignancies are poised to benefit from ActX testing. To ensure DPYD results are available at the initiation of adjuvant chemotherapy, the test is needed perioperatively.

- Smilow oncology pharmacists will identify qualifying patients and place the pharmacogenomics panel laboratory order, with the respective surgeon's co-signature, during their inpatient surgical encounter.
- Pharmacists will coordinate result return and any necessary therapeutic changes, while also documenting findings important to patient care. Pharmacists will also engage the patient's medical oncologist to adjust fluoropyrimidine dosing, if indicated.
- Smilow Cancer Hospital Pharmacy Contacts: Stephanie Trexler, PharmD, BCOP; Jane Lee, PharmD, BCOP; Man Yee Merl, PharmD, BCOP; System Clinical Coordinator, Pharmacogenomics: Rebecca Pulk, PharmD, MS
- Pharmacogenomics Service Email: [PGx@ynhh.org](mailto:PGx@ynhh.org)

### **NCODA's Positive Quality Intervention in Action**

To promote higher quality patient care, the National Community Oncology Dispensing Association, Inc. (NCODA) created the NCODA Positive Quality Intervention (PQI) as a resource for healthcare providers. In the current issue, Anne Chiang, MD, PhD, Evanica Rosselli, RN, MSN, Darren Luon, PharmD, BCOP, and Krystal Zoock, CPhT, discussed how utilizing the Selpercatinib Genomic Testing Management PQI and the Selpercatinib Management PQI elevates patient care.

[Learn More](#)

### **NCCN Annual Report**

The National Comprehensive Cancer Network (NCCN) recently published their [2021 Annual Report](#). In collaboration with Yale Cancer Center and Smilow Cancer Hospital, NCCN continued to update and share relevant and influential guidance while working to improve the quality, effectiveness, equitability, and accessibility of cancer care globally over the last year. This report reflects on the accomplishments of 2021 and shares new initiatives that support NCCN's mission.

The Annual Report also highlights the NCCN Board of Directors, Committees, and Guidelines Panels, including [participation on NCCN Committees and Guidelines Panels](#).

**Best regards,**

**Kevin G. Billingsley, MD, MBA**  
Chief Medical Officer

Smilow Cancer Hospital

**Kim Slusser, MSN, RN, CHPN, NEA-BC**

Vice President for Patient Services

Smilow Cancer Hospital

